| Prev Close | 92.32 |
| Day Low/High | 91.51 / 94.56 |
| 52 Wk Low/High | 70.89 / 92.87 |
Merck & Co., Inc. (MRK)
93.00
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2528.80B |
| Market Cap | 233.46B |
| P/E Ratio | 17.80 |
| Div & Yield | N.A. (N.A) |
Latest News
Any Bounce in This Nasty Bear Market Should Be Viewed With Caution
For now, any rebound is a short-term trading opportunity and nothing more.
3 Name-Brand Stocks That Traders Might Take a Stab at in This Rotten Market
Rather than try to catch falling knives, traders should give a look at Merck, IBM and Procter & Gamble.
The MOAT ETF Could Float Your Boat If You Desire Good Relative Performance
The VanEck Morningstar Wide Moat ETF has held its own against the SPDR S&P 500 ETF and diversified giant Berkshire Hathaway.
As Pfizer Faces a Period of Volatility, Here's My Plan for the Shares
There will have to be an adjustment made to their Covid vaccine and others at some point.
In a Sick Market, Can Pharmas Help?
Let's check the charts of three drug names, Merck, Eli Lilly and Bristol-Myers Squibb.
Premarket Movers
Upside - +74% (enters strategic agreement with Immune Therapeutics for rights to low dose naltrexone) - +18% (earnings, guidance) - +16% (earnings, guidance) - +14% (earnings) - +11% (earnings, guidance) - +10% (earnings, guidance) - +9.1% (highligh...
The Good, the Bad and the Ugly, Trading Meta Platforms, What's Down Teladoc?
Wednesday's session was dominated by traders, algorithmic traders for sure, but traders nonetheless. The PMs mostly sat on their hands.
Just a Spoonful of Profits to Help the Merck Go Down
Here's where I think MRK can go and how to play it.
BioXcel Therapeutics: Here's Why I'm Buying and How You Can Trade It
After receiving an FDA approval, the small-cap biotech looks well positioned as a covered call candidate.
7 Best Buys in Biotech and Drug Development
Recently poor sector performance is creating opportunity for long-term investors.
The Selling in Growth Names Is Gaining Some Momentum
It's always surprising how quickly stocks can reverse for no real reason.
Let's Put the IQ Healthy Hearts ETF Through Its Paces
A closer look at the fund's composition leads to a few head-scratchers, but most of the names seem to fairly represent its focus.
Melting Candles, Meta, Spotify, Tech-Ageddon, Jobs Mess, Healthcare Hot Tickets
Just a week ago Jerome Powell referred to the labor market as 'strong.' Now, economists, traders, investors, and the public are just not quite sure what to expect Friday.
Did Apple Save the Market?
Probably not, but there are some positives there that will help in the search for a bottom.
Markets, Treasuries, Taxes, 2022 Expectations, FOMC, 2 Stocks to Watch
Negative returns for 2022? It's a midterm election year. We will see increased volatility. Anything is possible, and it would not surprise me.
Markets, Data Dump, Student Loans, TikTok, Merck, Trading Salesforce
Friday might be a market holiday, but it became obvious on Wednesday that trading volumes had started to truly dwindle.
Omicron, Biden, Market Rally, Covid Fighting Pills, Trading Apple
Perhaps the rally had been set up by the depth of the pressure placed on financial markets over the prior three days. Perhaps.
Let's Check Up on 2 Immunology-Focused Oncology ETFs
Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.
A Little This, a Little That
Looking at the top five in the DJIA: * American Express breaches its 20-day moving average ($174.93) * Salesforce back to the mid-$260s after a big spill * Intel is gapping above its 50-day moving average ($51.13) after the announcement of its plan ...
Should Investors Believe in Bounces as Markets Get Choppy?
Sector selection will remain paramount as pandemic effects continue to permeate.
Johnson & Johnson Joins the Breakup Club: Here's How to Play It
J&J will be separating into two distinct firms, but not right away.
FibroGen Feedback
I continue to get good feedback with regard to FibroGen. The above is part of a publication on myelodysplastic syndrome. I would note that Acceleron is being acquired by Merck for $11 billion. Acceleron has a drug on market which treats 15%-20% ...
Riders on the Storm, More D.C. Nonsense, Early Take on Apple and Amazon
The two big names disappointed after hours Thursday, but one is more of a concern than the other.
The Worms Turns, O Bank of Canada, Flattening Curve, Ford on Fire, Apple, Amazon
We had almost forgotten that sometimes Mr. Market can still land a ham-sized fist squarely upon that beaming smile of yours.
What a Week, China's Troubles, Hypersonic Weapons, Earnings, FDA Drug Approvals
The lack of urgency at the FDA, as it is in the defense space, is alarming.
Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
